Heart failure & cardiomyopathies
Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure
Main findingResult — go to the resultAdjusted hazard ratio 0.56 95% CI 0.43–0.74Authors' conclusion
The use of SGLT2i was associated with a lower risk of AF recurrence and the composite outcome of cardiovascular death, thrombotic events, or cardiovascular hospitalization after catheter ablation for AF in patients with HF.
Study context
- Population
- Heart failure (HF) patients with atrial fibrillation (AF) undergoing catheter ablation, China-AF Registry, January 2017–December 20221:1 matched cohort
- Participants
- 368 vs 368
- Exposure
- SGLT2i vs no SGLT2i at discharge after AF ablation
- SGLT2in = 368
- Non-SGLT2in = 368reference
- Outcome
- AF recurrence after a 3-month blanking period
Methodological detailspropensity-score matched, registry (China-AF Registry)
- Propensity-score matched
- Registry (China-AF Registry)
Main finding
As reported in the abstract
Adjusted hazard ratio
0.56
95% CI 0.43–0.74
P < 0.001
Events by group
SGLT2i vs Non-SGLT2i
adjusted HR 0.56 (95% CI 0.43–0.74); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted HR (95% CI) | P value | |
|---|---|---|---|
| Composite of CV death, thrombotic events or CV hospitalisation | 0.58 (0.41–0.80) | P = 0.001 | |
| 0.512Adjusted hazard ratio (log scale) |
All-cause mortality, CV death, thrombotic events
- Trend toward benefit, differences insignificant between the 2 groups
Original publication
Impact of sodium-glucose cotransporter 2 inhibitor on recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation in patients with heart failure. Heart Rhythm. Published 20 August 2024. doi:10.
Summarised from the published abstract; every number is checked against it